Quipt Home Medical > Press Releases > Quipt Home Medical to Commence Trading on Nasdaq

Quipt Home Medical to Commence Trading on Nasdaq

CINCINNATI, May 26, 2021 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (“Quipt” or the “Company”) (TSXV:QIPT; OTCQX:PTQQD), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce that its common shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the trading ticker symbol “QIPT”. Trading on the Nasdaq is expected to commence at market open on May 27, 2021.

“This Nasdaq listing is an incredible achievement for our Company and its shareholders, as we continue our mission of providing superior patient care for at home respiratory patients across the United States. This listing reflects the substantial organizational growth experienced by our Company and our evolution as a publicly traded company over the last several years,” commented Greg Crawford, CEO and Chairman of Quipt. “Through a multitude of strategic initiatives, we continue to build our aperture of opportunity for strong organic growth and robust M&A activity in the 2nd half of the year and are excited to elevate our Company’s public profile. We believe the Nasdaq listing will assist us in expanding our shareholder base geographically and help provide more liquidity over time.”

The Company’s common shares will continue to be listed on the TSX Venture Exchange under the symbol “QIPT”.


ABOUT QUIPT HOME MEDICAL CORP.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking information” as such term is ‎‎‎‎defined in applicable Canadian and United States securities legislation. The words “may”, “would”, “could”, “should”, “potential”, ‎‎‎‎‎”will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate ‎‎‎‎to the Company, including: the Company having strong organic ‎growth and robust M&A activity in the 2nd half of the year; and the Nasdaq listing expanding the Company’s shareholder base geographically and helping to provide more ‎liquidity over time; are intended to identify ‎forward-looking information. All ‎statements other than ‎statements of ‎historical fact may be forward-looking ‎information. Such statements reflect the ‎Company’s current ‎views and ‎intentions with respect to future events, and ‎current information available to the ‎Company, and are ‎subject to ‎certain risks, uncertainties and assumptions. Many factors ‎‎could ‎cause the actual results, performance or achievements that may be expressed or ‎implied by such forward-‎‎looking ‎information to vary from those described herein should one or more of these risks ‎or uncertainties ‎‎materialize. ‎Examples of such risk factors include, without limitation: credit; market (including ‎equity, commodity, ‎‎foreign ‎exchange and interest rate); liquidity; operational (including technology and ‎infrastructure); ‎‎reputational; ‎insurance; strategic; regulatory; legal; environmental; capital adequacy; the ‎general business and ‎‎economic ‎conditions in the regions in which the Company operates; the ability of the ‎Company to execute on key ‎‎priorities, ‎including the successful completion of acquisitions, business retention, and ‎strategic plans and to ‎‎attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎the ability to ‎‎implement business ‎strategies and pursue business opportunities; low profit market segments; ‎disruptions in or ‎‎attacks (including ‎cyber-attacks) on the Company’s information technology, internet, network ‎access or other ‎‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎criminal ‎‎behavior to which ‎the Company is exposed; the failure of third parties to comply with their obligations to ‎the ‎‎Company or its ‎affiliates; the impact of new and changes to, or application of, current laws and regulations; ‎‎‎decline of ‎reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; ‎‎‎‎dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult ‎‎‎‎litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased ‎‎‎‎funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds ‎‎‎‎and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, ‎‎‎‎and methods used by the Company; the occurrence of natural and unnatural catastrophic events ‎and claims ‎‎‎‎resulting from such events; and risks related to COVID-19 including various recommendations, orders ‎and ‎‎‎measures of governmental ‎authorities ‎to try to limit the pandemic, including travel restrictions, border closures, ‎‎‎‎non-essential business ‎closures, ‎quarantines, self-isolations, shelters-in-place and social distancing, disruptions ‎‎‎to ‎markets, economic ‎activity, ‎financing, supply chains and sales channels, and a deterioration of general ‎‎‎economic ‎conditions ‎including a ‎possible national or global recession‎; as well as those risk factors discussed or ‎‎‎referred to in ‎the Company’s disclosure ‎documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected ‎‎‎manner, or should ‎assumptions ‎underlying the forward-looking information prove incorrect, the actual results or ‎‎‎events may differ ‎materially ‎from the results or events predicted. Any such forward-looking information is ‎‎‎expressly qualified in its ‎entirety by ‎this cautionary statement. Moreover, the Company does not assume ‎‎‎responsibility for the accuracy or ‎‎completeness of such forward-looking information. The forward-looking ‎‎‎information included in this press release ‎is ‎made as of the date of this press release and the Company undertakes ‎‎‎no obligation to publicly update or revise ‎any ‎forward-looking information, other than as required by applicable ‎‎‎law.‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in ‎the policies of ‎the ‎TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of ‎this release.‎

For further information please visit our website at www.quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
[email protected]

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
[email protected]